MXPA05002943A - Acido eicosapentaenoico (epa) para el tratamiento de la anorexia nerviosa (an) y bulimia. - Google Patents

Acido eicosapentaenoico (epa) para el tratamiento de la anorexia nerviosa (an) y bulimia.

Info

Publication number
MXPA05002943A
MXPA05002943A MXPA05002943A MXPA05002943A MXPA05002943A MX PA05002943 A MXPA05002943 A MX PA05002943A MX PA05002943 A MXPA05002943 A MX PA05002943A MX PA05002943 A MXPA05002943 A MX PA05002943A MX PA05002943 A MXPA05002943 A MX PA05002943A
Authority
MX
Mexico
Prior art keywords
epa
treatment
acid
patient
bulimia
Prior art date
Application number
MXPA05002943A
Other languages
English (en)
Spanish (es)
Inventor
Ayton Agnes
Original Assignee
Laxdale Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9944164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05002943(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laxdale Ltd filed Critical Laxdale Ltd
Publication of MXPA05002943A publication Critical patent/MXPA05002943A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
MXPA05002943A 2002-09-16 2003-09-16 Acido eicosapentaenoico (epa) para el tratamiento de la anorexia nerviosa (an) y bulimia. MXPA05002943A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0221480.7A GB0221480D0 (en) 2002-09-16 2002-09-16 Treatment of anorexia nervosa (AN) and bulimia
PCT/GB2003/003985 WO2004024136A1 (en) 2002-09-16 2003-09-16 Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia

Publications (1)

Publication Number Publication Date
MXPA05002943A true MXPA05002943A (es) 2005-06-03

Family

ID=9944164

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05002943A MXPA05002943A (es) 2002-09-16 2003-09-16 Acido eicosapentaenoico (epa) para el tratamiento de la anorexia nerviosa (an) y bulimia.

Country Status (20)

Country Link
US (1) US20060135608A1 (enExample)
EP (1) EP1556028A1 (enExample)
JP (1) JP2006503031A (enExample)
KR (1) KR20050042823A (enExample)
CN (1) CN1694694A (enExample)
AU (1) AU2003269138A1 (enExample)
BR (1) BR0317857A (enExample)
CA (1) CA2499142A1 (enExample)
GB (1) GB0221480D0 (enExample)
HR (1) HRP20050245A2 (enExample)
IS (1) IS7744A (enExample)
MX (1) MXPA05002943A (enExample)
NO (1) NO20051847L (enExample)
NZ (1) NZ538793A (enExample)
PL (1) PL375726A1 (enExample)
RS (1) RS20050226A (enExample)
RU (1) RU2330653C2 (enExample)
TW (1) TW200410682A (enExample)
WO (1) WO2004024136A1 (enExample)
ZA (1) ZA200502161B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
EP1683519A4 (en) * 2003-11-14 2009-04-01 Mochida Pharm Co Ltd PREVENTIVE / THERAPEUTIC AGENT FOR TREATING SPEECH DISORDERS
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
WO2008081989A1 (ja) 2006-12-28 2008-07-10 Suntory Holdings Limited 神経再生剤
CA2672513C (en) 2007-02-15 2010-05-25 Centre De Recherche Sur Les Biotechnologies Marines Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
US8816110B2 (en) 2007-02-15 2014-08-26 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
EP2136844B1 (en) 2007-03-20 2018-10-31 SCF Pharma Inc. Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
CN108096209A (zh) * 2009-06-15 2018-06-01 阿马里纳制药公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
CA2825037A1 (en) * 2011-02-11 2012-08-16 E.I. Du Pont De Nemours And Company An eicosapentaenoic acid concentrate
US9447020B2 (en) 2013-10-31 2016-09-20 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
RU2545988C1 (ru) * 2013-11-12 2015-04-10 Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр Департамента здравоохранения города Москвы Способ лечения хронического запора и функциональной анорексии
CN111971041A (zh) 2018-02-07 2020-11-20 Scf制药股份有限公司 多不饱和脂肪酸单甘油酯、组合物、方法及其用途
US20210130897A1 (en) * 2018-04-16 2021-05-06 Quadrant Biosciences Inc. Salivary microrna levels in anorexia nervosa provide a liquid biopsy of metabolic and neuropsychiatric status
CN112384212A (zh) 2018-05-03 2021-02-19 Scf制药股份有限公司 多不饱和脂肪酸单甘油酯、其组合物、方法和用途
CN109276262B (zh) * 2018-07-30 2021-01-26 中国科学院心理研究所 一种用于筛选高危进食障碍的检测系统
US12226390B2 (en) 2019-07-21 2025-02-18 Scf Pharma Inc. Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof
EP4125836A1 (en) * 2020-03-27 2023-02-08 Homeostasis Therapeutics, Limited Method of treatment for anorexia nervosa, bulimia and related clinical syndromes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes

Also Published As

Publication number Publication date
GB0221480D0 (en) 2002-10-23
TW200410682A (en) 2004-07-01
ZA200502161B (en) 2005-09-15
EP1556028A1 (en) 2005-07-27
JP2006503031A (ja) 2006-01-26
NO20051847L (no) 2005-04-15
HRP20050245A2 (en) 2005-10-31
CA2499142A1 (en) 2004-03-25
RU2005107416A (ru) 2006-01-20
NZ538793A (en) 2007-05-31
RU2330653C2 (ru) 2008-08-10
CN1694694A (zh) 2005-11-09
RS20050226A (sr) 2007-09-21
BR0317857A (pt) 2005-12-06
US20060135608A1 (en) 2006-06-22
IS7744A (is) 2005-03-15
PL375726A1 (en) 2005-12-12
AU2003269138A1 (en) 2004-04-30
KR20050042823A (ko) 2005-05-10
WO2004024136A1 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
RU2330653C2 (ru) Эйкозапентаеновая кислота (эпк) для лечения нервно-психической анорексии (на) и булимии
Marangell et al. Omega‐3 fatty acids for the prevention of postpartum depression: Negative data from a preliminary, open‐label pilot study
Aiges et al. Home nocturnal supplemental nasogastric feedings in growth-retarded adolescents with Crohn's disease
Sydenstricker et al. Observations on the egg white injury in man: And its cure with a biotin concentrate
Kowdley et al. Vitamin E deficiency and impaired cellular immunity related to intestinal fat malabsorption
JP2023100870A (ja) 対象におけるマイトファジーを改善するための方法
JP2020504134A (ja) 外傷性脳損傷のためのグリセリル３−ヒドロキシブチラート
JP2020514338A (ja) 対象におけるマイトファジーを改善するための方法
Nishioka et al. The concept of aggressive nutrition therapy and clinical indication: a position paper
JP7294147B2 (ja) 侵害受容性疼痛の予防又は改善用組成物
JP6360172B2 (ja) チグリンアルデヒドを使用する組成物及び方法
JP6368368B2 (ja) ｐ−アニスアルデヒドを使用する組成物及び方法
Roberts The syndrome of narcolepsy and diabetogenic hyperinsulinism in the american negro: Its relationship to the pathogenesis of diabetes mellitus, obesity, dysrhythmias, and accelerated cardiovascular disease
Stepien et al. The Challenges of a Successful Pregnancy in a Patient with Adult Refsum’s Disease due to Phytanoyl-CoA Hydroxylase Deficiency
Brown et al. Topiramate and weight loss in patients with neurodevelopmental disabilities
CN114916661A (zh) 天然食品组合物及其应用
WO2021182403A1 (ja) 認知機能の低下抑制および／または改善用組成物
Shorr Endocrine problems in adolescence
JP2000302677A (ja) カルニチン自己産生能改善作用を有する医薬および食品・飼料組成物
Myers Thyroid Disorders
Jyothi A Comparitive Clinical Study to Evaluate the Effect of Udwartana Chikitsa and Lekhana Basti in Medoroga/Sthoulya WSR to Obesity
Bluestone Two young women with signs of CNS catastrophe
Taper Nurses Alert
Prieto Aspects of the present problem of gonorrhoea in Spain
SENSIBILITY were defatted by prolonged extraction with benzoyl chloride. There was no preliminary acid treatment

Legal Events

Date Code Title Description
FA Abandonment or withdrawal